ES2393243T3 - Imidazol carboxamidas - Google Patents

Imidazol carboxamidas Download PDF

Info

Publication number
ES2393243T3
ES2393243T3 ES09790351T ES09790351T ES2393243T3 ES 2393243 T3 ES2393243 T3 ES 2393243T3 ES 09790351 T ES09790351 T ES 09790351T ES 09790351 T ES09790351 T ES 09790351T ES 2393243 T3 ES2393243 T3 ES 2393243T3
Authority
ES
Spain
Prior art keywords
methyl
mmol
compound
trifluoromethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09790351T
Other languages
English (en)
Spanish (es)
Inventor
Albert Khilevich
Bin Liu
Daniel Ray Mayhugh
Jeffrey Michael Schkeryantz
Deyi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2393243T3 publication Critical patent/ES2393243T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
ES09790351T 2008-07-18 2009-07-14 Imidazol carboxamidas Active ES2393243T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81774 2002-02-20
US8177408P 2008-07-18 2008-07-18
PCT/US2009/050440 WO2010009062A1 (en) 2008-07-18 2009-07-14 Imidazole carboxamides

Publications (1)

Publication Number Publication Date
ES2393243T3 true ES2393243T3 (es) 2012-12-19

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09790351T Active ES2393243T3 (es) 2008-07-18 2009-07-14 Imidazol carboxamidas

Country Status (19)

Country Link
US (1) US7754742B2 (https=)
EP (1) EP2318375B1 (https=)
JP (1) JP5379227B2 (https=)
KR (1) KR101287713B1 (https=)
CN (1) CN102099344B (https=)
AR (1) AR074631A1 (https=)
BR (1) BRPI0915977A2 (https=)
CA (1) CA2731215C (https=)
CY (1) CY1113315T1 (https=)
DK (1) DK2318375T3 (https=)
EA (1) EA018434B1 (https=)
ES (1) ES2393243T3 (https=)
HR (1) HRP20120830T1 (https=)
MX (1) MX2011000611A (https=)
PL (1) PL2318375T3 (https=)
PT (1) PT2318375E (https=)
SI (1) SI2318375T1 (https=)
TW (1) TW201006801A (https=)
WO (1) WO2010009062A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CN103502218B (zh) * 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107207449B (zh) * 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
CN108137566B (zh) 2015-10-06 2021-05-25 豪夫迈·罗氏有限公司 三唑衍生物
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
EP3464246B1 (en) 2016-05-27 2020-07-08 H. Hoffnabb-La Roche Ag Pyrazol compounds as eaat3 inhibitors
CN109563049B (zh) 2016-10-14 2022-11-29 豪夫迈·罗氏有限公司 作为eaat3抑制剂的咪唑化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES494769A0 (es) 1979-09-05 1981-07-16 Glaxo Group Ltd Un procedimiento para la pre-paracion de fenoxialcoxifenil- derivados.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
DE69210091T2 (de) 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
WO2001056990A2 (en) 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
JP2006502143A (ja) * 2002-08-26 2006-01-19 メルク　エンド　カムパニー　インコーポレーテッド 向代謝型グルタミン酸受容体のアセトフェノン増強因子
EP1773792A1 (en) 2004-07-30 2007-04-18 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
EP1773774A4 (en) * 2004-07-30 2009-12-30 Merck & Co Inc HETEROCYCLIC ACETOPHENONE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CN101048157A (zh) 2004-10-25 2007-10-03 默克公司 代谢型谷氨酸受体的杂环二氢茚酮增强剂
ES2333979T3 (es) 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
KR20070106690A (ko) 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Also Published As

Publication number Publication date
JP5379227B2 (ja) 2013-12-25
MX2011000611A (es) 2011-03-01
CN102099344B (zh) 2013-10-30
KR101287713B1 (ko) 2013-07-23
CN102099344A (zh) 2011-06-15
CA2731215C (en) 2013-08-27
EP2318375B1 (en) 2012-09-19
SI2318375T1 (sl) 2012-11-30
TW201006801A (en) 2010-02-16
KR20110022676A (ko) 2011-03-07
EA018434B1 (ru) 2013-07-30
WO2010009062A1 (en) 2010-01-21
EP2318375A1 (en) 2011-05-11
DK2318375T3 (da) 2012-10-08
CY1113315T1 (el) 2016-04-13
AU2009271105A1 (en) 2010-01-21
US7754742B2 (en) 2010-07-13
PT2318375E (pt) 2012-10-22
US20100016373A1 (en) 2010-01-21
HRP20120830T1 (hr) 2012-11-30
PL2318375T3 (pl) 2013-02-28
AR074631A1 (es) 2011-02-02
EA201170227A1 (ru) 2011-06-30
CA2731215A1 (en) 2010-01-21
JP2011528658A (ja) 2011-11-24
BRPI0915977A2 (pt) 2018-10-30

Similar Documents

Publication Publication Date Title
ES2393243T3 (es) Imidazol carboxamidas
AU2021204985B2 (en) Compositions and methods of modulating 15-pgdh activity
RU2733741C2 (ru) Тетразамещенные алкеновые соединения и их применение
WO2011045415A2 (en) New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
JP4906839B2 (ja) 置換ｎ−スルホニルアミノフェニルエチル−２−フェノキシアセトアミド化合物
ES2382876T3 (es) Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
CN1984895B (zh) 昔萘福林衍生物的合成及应用
SK2012003A3 (en) Phenoxybenzylamine derivatives as selective re-uptake inhibitors
UA75067C2 (en) Diphenyl ethers, pharmaceutical composition containing them, use thereof, a method for treatment (variants), a method for obtaining thereof and method for producing intermediary compounds
ES2308562T3 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
WO2018098251A1 (en) Tetrasubstituted alkene compounds and their use
ES2369510T3 (es) Moduladores del receptor de la vitamina d.
AU2009271105B2 (en) Imidazole carboxamides
EP4506346A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof, and use thereof
CN113735788B (zh) 布洛芬三唑硫醇衍生物及其在制备新冠病毒抑制剂中应用
CN113735787A (zh) 萘普生三唑硫酮衍生物及其在制备新冠病毒抑制剂中应用
BR112021018303B1 (pt) Composto inibidor de pequenas moléculas de fatores de transcrição de tead ou sal farmaceuticamente aceitável deste, composição farmacêutica e uso destes
HUP0501212A2 (en) Optical isomers of dihydro-2,3-benzodiazepin, their stereoselective synthesis, pharmaceutical compositions containing them and their use